ES2143996T3 - Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv. - Google Patents

Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.

Info

Publication number
ES2143996T3
ES2143996T3 ES93112337T ES93112337T ES2143996T3 ES 2143996 T3 ES2143996 T3 ES 2143996T3 ES 93112337 T ES93112337 T ES 93112337T ES 93112337 T ES93112337 T ES 93112337T ES 2143996 T3 ES2143996 T3 ES 2143996T3
Authority
ES
Spain
Prior art keywords
hcv
determination
procedure
antigens
peptidic antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93112337T
Other languages
English (en)
Other versions
ES2143996T5 (es
Inventor
Christoph Dr Seidel
Ursula-Henrike Dr Wienhues
Hubert Dr Bayer
Gunther-Gerhard Prof Dr Jung
Hans Georg Ihlenfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25917283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2143996(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of ES2143996T3 publication Critical patent/ES2143996T3/es
Application granted granted Critical
Publication of ES2143996T5 publication Critical patent/ES2143996T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBEN NUEVOS ANTIGENOS DE PEPTIDOS HCV. ESTOS ANTIGENOS DE PEPTIDOS SON APROPIADOS PARA DETERMINAR ANTICUERPOS HCV COMO INMUNOGENOS PARA LA PRODUCCION DE ANTICUERPOS FRENTE A HCV Y COMO VACUNA PARA PRODUCIR VACUNAS FRENTE A HCV.
ES93112337T 1992-08-07 1993-08-02 Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv. Expired - Lifetime ES2143996T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4226093 1992-08-07
DE4226093 1992-08-07
DE4240980A DE4240980A1 (de) 1992-08-07 1992-12-05 HCV Peptidantigene und Verfahren zur Bestimmung von HCV
DE4240980 1992-12-05

Publications (2)

Publication Number Publication Date
ES2143996T3 true ES2143996T3 (es) 2000-06-01
ES2143996T5 ES2143996T5 (es) 2007-10-16

Family

ID=25917283

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93112337T Expired - Lifetime ES2143996T5 (es) 1992-08-07 1993-08-02 Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.

Country Status (9)

Country Link
US (1) US5674676A (es)
EP (2) EP0967223A3 (es)
JP (1) JP2666903B2 (es)
KR (1) KR940003967A (es)
AT (1) ATE189683T1 (es)
AU (1) AU655112B2 (es)
CA (1) CA2103533A1 (es)
DE (2) DE4240980A1 (es)
ES (1) ES2143996T5 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430973A1 (de) * 1994-07-25 1996-02-01 Boehringer Mannheim Gmbh Hapten-markierte Peptide
US5670310A (en) * 1994-07-29 1997-09-23 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for differential diagnosis of acute and chronic hepatitis c virus infection
JP3665371B2 (ja) * 1994-08-31 2005-06-29 株式会社先端生命科学研究所 Ｃ型肝炎ウイルス感染又はグループ判定のためのエピトープキメラ抗原ペプチド、その製法、及びそれを使用する感染又はグループ判定法
CA2172305A1 (en) * 1995-03-30 1996-10-01 Muneo Aoyama Multiple antigenic peptide comprising at least two hepatitis c virus-associated peptides
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
DE19637718A1 (de) 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
FR2775690B1 (fr) * 1998-03-09 2001-12-14 Bio Merieux Anticorps monoclonal et utilisations pour detecter des antigenes de la proteine core de vhc
JP2008509654A (ja) * 2004-06-01 2008-04-03 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド
JP4615567B2 (ja) * 2005-04-19 2011-01-19 株式会社グリーンペプタイド Ｃ型肝炎ウイルス感染に関連する肝疾患の予後の予測
JP2009018990A (ja) * 2005-10-25 2009-01-29 Univ Kurume Ｃ型肝炎ウイルス由来ペプチド
FR2987836A1 (fr) * 2012-03-09 2013-09-13 Biomerieux Sa Peptides d'interference et procede de detection de microorganismes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3640412A1 (de) * 1986-11-26 1988-06-09 Boehringer Mannheim Gmbh Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
EP0445801A3 (en) * 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
EP0933426A1 (en) * 1990-06-25 1999-08-04 The Research Foundation for Microbial Diseases of Osaka University Non-a, non-b hepatitis virus genomic cdna fragments and antigen polypeptides
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
AU673135B2 (en) * 1990-08-25 1996-10-31 New York Blood Center, Inc., The Non-A, non-B hepatitis virus antigen, diagnostic methods and vaccines
DE59109221D1 (de) * 1990-11-03 2001-11-15 Dade Behring Marburg Gmbh HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
DK0489968T3 (da) * 1990-12-14 1997-03-24 Innogenetics Nv Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
AU1459792A (en) * 1991-01-14 1992-08-27 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
DE69232871T2 (de) * 1991-06-24 2003-05-08 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv

Also Published As

Publication number Publication date
EP0582243A2 (de) 1994-02-09
AU655112B2 (en) 1994-12-01
EP0582243A3 (de) 1995-03-15
KR940003967A (ko) 1994-03-14
EP0967223A2 (de) 1999-12-29
US5674676A (en) 1997-10-07
AU4439993A (en) 1994-02-10
EP0582243B2 (de) 2007-03-07
EP0967223A3 (de) 2000-09-06
ATE189683T1 (de) 2000-02-15
ES2143996T5 (es) 2007-10-16
DE59309950D1 (de) 2000-03-16
CA2103533A1 (en) 1994-02-08
JP2666903B2 (ja) 1997-10-22
JPH06247997A (ja) 1994-09-06
DE4240980A1 (de) 1994-02-10
EP0582243B1 (de) 2000-02-09

Similar Documents

Publication Publication Date Title
HU9500571D0 (en) Retro-, inverso-, and retro-inverso synthetic peptide analogues
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
ES2174931T3 (es) Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1.
ATE475675T1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
HUP9902438A2 (hu) Parapoxvírus vektorok
FI950405A0 (fi) Heikosti immunogeenisten antigeenien ja synteettisten peptidikantajien konjugaatit sekä niitä sisältävät rokotteet
ES2111167T3 (es) Compuestos peptidicos.
ATE328068T1 (de) Papillomavirus vakzine
DK0527760T3 (da) Fremgangsmåder og præparater til vaccination mod HIV
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
ES2013328A6 (es) Un metodo para detectar anticuerpos contra antigenos hiv-1.
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
DE3685651D1 (de) Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
DK1370284T3 (da) Bakteriofag-medieret immunisering
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ATE248601T1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
HUP0202770A2 (hu) Humán papillómavírus oltóanyag
ES2149822T3 (es) Peptidos inmunorreactivos procedentes del virus de epstein-barr.
ES2037795T3 (es) Procedimiento para la preparacion del antigeno hrpii de plasmodium falciparum sge2.
ES2032812T3 (es) Vacuna.
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ATE95422T1 (de) Ein synthetisches nonapeptid zur verwendung als adjuvant.
ZA888580B (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 582243

Country of ref document: ES